SCHEMBL724712

SCHEMBL724712

CS(=O)(=O)OCCCn1ccnn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MMP9 P14780 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
ATP4A P20648 1/20 0.35
ATP4B P51164 1/20 0.35
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33
APH1B Q8WW43 1/20 0.33
NCSTN Q92542 1/20 0.33
APH1A Q96BI3 1/20 0.33
PSENEN Q9NZ42 1/20 0.33
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CYP19A1 P11511 1/20 0.32
SRC P12931 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5511848 0.90 KDM4E (0.39) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL16426339 0.77 CYP24A1 (0.43) KDM4EALDH1A1MMP9ATP4AATP4B
SCHEMBL10192245 0.77 ATP4A (0.39) ALDH1A1ATP4AATP4BSLC6A2SLC6A4
SCHEMBL16555972 0.77 ALDH1A1 (0.45) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL17787935 0.74 ATP4A (0.37) KDM4EATP4AATP4BSLC6A2SLC6A4
SCHEMBL22704634 0.73 SLC6A2 (0.36) ALDH1A1ATP4AATP4BSLC6A2SLC6A4
SCHEMBL24465605 0.73 CYP19A1 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL31295219 0.72 KDM4E (0.52) KDM4EUSP2ALDH1A1LMNAMMP9
SCHEMBL14587709 0.72 SLC6A2 (0.36) ALDH1A1ATP4AATP4BSLC6A2SLC6A4
Sulfuric Acid SCHEMBL16340543 0.71 ALDH1A1 (0.38) ALDH1A1TSHRPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3026049-B1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE DONG A ST CO LTD (KR) 2021-09-22 EP disclosed
US-9771348-B2 Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate DONG-A ST CO., LTD (KR) 2017-09-26 US disclosed
US-9771348-B2 Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate DONG-A ST CO., LTD (KR) 2017-09-26 US disclosed
US-20160185751-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE DONG-A ST CO., LTD (KR) 2016-06-30 US disclosed
US-20160185751-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE DONG-A ST CO., LTD (KR) 2016-06-30 US disclosed
EP-2560955-B1 NOVEL BENZAMIDE DERIVATIVES DONG A PHARM CO LTD (KR) 2016-06-29 EP disclosed
EP-3026049-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE Dong-A ST Co., Ltd. (KR) 2016-06-01 EP disclosed
EP-3026049-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE Dong-A ST Co., Ltd. (KR) 2016-06-01 EP disclosed
CN-105636946-A Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate DONG A ST CO LTD 2016-06-01 CN disclosed
US-9221790-B2 Benzamide derivatives DONG-A PHARM. CO., LTD. (KR) 2015-12-29 US disclosed
WO-2015012515-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE 동아에스티 주식회사 (KR) 2015-01-29 WO disclosed
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM. CO., LTD. (KR) 2013-04-04 US disclosed
EP-2560955-A2 NOVEL BENZAMIDE DERIVATIVES Dong-A Pharm.Co., Ltd. (KR) 2013-02-27 EP disclosed
WO-2011132901-A2 NOVEL BENZAMIDE DERIVATIVES DONG-A PHARM.CO., LTD. (KR) 2011-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185751-A1 METHOD FOR PREPARING BENZAMIDE DERIVATIVE, NOVEL INTERMEDIATE USED IN PREPARATION OF BENZAMIDE, AND METHOD FOR PREPARING NOVEL INTERMEDIATE HTR4, HTR5A, HTR2B KDM4E 719/4885USP2 3109/4885ALDH1A1 1079/4885
US-20130085160-A1 NOVEL BENZAMIDE DERIVATIVES HTR4, GPR4, HTR5A KDM4E 1161/4885USP2 2941/4885ALDH1A1 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.